Recent data suggest that antidepressants are associated with incident diabetes but the possible pharmacological mechanism is still questioned. The aim of the present study was to evaluate antidepressant's risk for reporting diabetes using disproportionality analysis of the FDA adverse events spontaneous reporting system (FAERS) database and to investigate possible receptor/transporter mechanisms involved.
Introduction
Drug-induced metabolic side effects are a major concern in psychopharmacology. Antipsychotics are strongly associated with the core components of metabolic syndrome (weight gain, disrupted glucose handling and dyslipidaemia), whereas antidepressants were thought initially to have quite neutral effects on glucose metabolism. Conversely, a recent meta-analysis of 20 prospective studies suggested that antidepressants are associated with incident diabetes, with a relative risk of 1.27 (95% CI: 1.19-1. 35) [1], while a systematic review proposed a possible causal relationship between antidepressant and new-onset diabetes [2] .
The exact mechanism of antidepressants' diabetogenic properties is still questioned and most studies suggest that the risk for diabetes could be further elucidated by considering the diverse pharmacodynamic profile of the drugs [1, 2] . The better-studied antipsychotics could provide insights on the possible mechanisms of antidepressant-induced diabetes. Several receptor mechanisms of antipsychotic-induced metabolic side effects have been suggested, such as antagonism of dopamine, histamine, muscarinic and serotonin receptors [3] . A recent pharmacoepidemiological-pharmacodynamic study in VigiBase suggested that antipsychotics with H 1 and 5-HT 2C antagonistic properties were associated with diabetes [4] . Similar receptor mechanisms could mediate antidepressant-induced metabolic side effects; in support, observational studies suggested that NET inhibition, as well as antagonism on 5-HT 2C , H 1 [5, 6] and M 3 receptors [7] , could explain the risk for diabetes.
In the present study, a combined pharmacovigilancepharmacodynamic approach was used [4, 8, 9] : (i) to detect a potential safety signal of antidepressants-induced type 2 diabetes (T2D) using disproportionality analysis in the FDA adverse events reporting system (FAERS), and (ii) to investigate the association between the risk for reporting diabetes and the occupancy on neurotransmitter receptors and transporters.
Methods
Case/non-case study of the FAERS database A case/non-case study was conducted using spontaneous reports submitted in FAERS between the first quarter of 2004 and the second quarter of 2017 (2017Q2). FAERS is a spontaneous adverse events database, consisting of individual safety reports, collected by the pharmaceutical industry, health professionals and consumers, mainly from the United States. The data consists of administrative information, patient demographics, adverse events, information about drug therapy, patient outcomes and type of reporter [10] . Data extraction was performed using the OpenVigil2.1-MedDRA, an open pharmacovigilance data extraction, mining and analysis tool of the FAERS database. OpenVigil2.1-MedDRA operates only on cleaned FDA data, that is to say deleting most duplicates or reports with missing data [11] . To ascertain a minimum quality of data, further data cleaning was performed, and reports with residual miss-mapping, errors or unknown drug name, age, gender and reporting year were excluded. Reports involving only adults were included.
In FAERS, adverse events are coded using the MedDRA ontology. Reports with diabetes were identified using the narrow scope of the standardized MedDRA query (SMQ) 'hyperglycaemia/new-onset diabetes mellitus', which is more specific for new-onset diabetes mellitus compared to the broad scope which includes less specific terms, such as 'weight increased'. All the other events were defined as non-cases. All reports including one or more of 22 FDA-approved antidepressants (amitriptyline, bupropion, citalopram, clomipramine, desipramine, desvenlafaxine, doxepin, duloxetine, escitalopram, fluoxetine, fluvoxamine, imipramine, maprotiline, milnacipran, mirtazapine, nefazodone, nortriptyline, paroxetine, sertraline, trazodone, trimipramine, venlafaxine) as suspected, interacting or concomitant were extracted. Non-FDA approved antidepressants (e.g. agomelatine, reboxetine) were not included because they would suffer from underreporting rates in FAERS. Recently FDA-approved antidepressants, such as levomilnacipran, vortioxetine and vilazodone, were not included, in order to avoid the reporting patterns during the first marketing years (studied period until the second quarter of 2017). Finally, monoamine oxidase inhibitors, a sparsely used category of antidepressants with different mechanism of action (enzyme inhibitors), which have been associated with hypoglycaemia [12] ,were also excluded. Additional extracted data were identity numbers of the report, gender, age, reporting year and associated drugs, while the source of the report was not available for extraction.
Concomitant medication could confound the results [13] , thus a number of drugs were excluded (Table S1 ). Reports with antidiabetics were excluded in order to avoid reverse causality, since they indicate pre-existing, but not incident, diabetes. Antipsychotics were excluded as they have been associated with diabetes and important notoriety bias has been considered for clozapine and olanzapine in FAERS [4] . Along with antipsychotics, reports with a combination of antidepressants were also not included, to avoid the competition bias of the former and parallel targeting on neurotransmitter receptors and transporters. Concomitant use of hyperglycaemic drugs was also previously defined as a potential confounder [14] [15] [16] . The risk for reporting diabetes was also adjusted for the further possible confounders: age, gender, reporting year and use of hyperglycaemic drugs.
Pharmacodynamic data
Receptor occupancy was selected to quantitate receptormediated mechanisms [4] and it was calculated using the pharmacological receptor theory [4, 17] 4 dopamine receptors and H 1 ) were extracted using the PDSP [18] and IUPHAR/BPS [19] databases, following this hierarchy based on availability. The mean value was calculated when more than one datum was available for one receptor. The mean Ki values of alpha adrenoceptors were calculated regardless of receptor subtypes. The total blood drug concentration (C max [ng ml À1 ]) was estimated using the maximum point of the therapeutic reference range reported in the Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology [20] . Nefazodone was not included in the former guidelines and its total blood concentration was extracted from a pharmacokinetic study on healthy male volunteers [21] . Τhe unbound drug fraction (Fu) was extracted from the Drugbank [22] and the molecular weights (M r [g mol À1 ]) of antidepressants extracted from the IUPHAR database [19] . The unbound blood concentration (Cr [nM]) was estimated using the equation Cr = 1000 * Fu * C max /M r .
Statistical analysis
Descriptive analysis. Study population characteristics were compared between cases and non-cases using the MannWhitney U-test for age and chi-squared for the categorical variables (age groups, gender, use of hyperglycaemic drugs and reporting year).
Disproportionality analysis. The association with reporting diabetes was expressed by the reporting odds ratio (ROR), which estimates the frequency of diabetes co-reported with the tested drugs compared with the other drugs. Disproportionality signals were detected when the number of reports was higher than three and ROR -95% CI was greater than one [10] . Apart from the crude ROR (cROR), the adjusted ROR (aROR) was calculated using multivariate logistic regression analysis including as covariates potential confounding factors as categorical variables, i.e. age, gender, reporting year and use of hyperglycaemic. For each antidepressant, the cROR and aROR were calculated to compare the proportion of diabetes with this individual antidepressant to the proportion of diabetes with the other antidepressants.
Relationship between disproportionality analysis and receptor occupancy. Pearson's correlation coefficients (r) between the aROR for diabetes and the degree of occupancy on each receptor investigated the relationship between occupancy and the risk for reporting diabetes. Antidepressants with less than three reports with diabetes were excluded, as well as degrees of occupancy less than 0.1% from the analysis [8] .
We assumed that the higher the degree of occupancy, the higher the risk for reporting diabetes, expressed as aROR for diabetes. In order to minimize the risk of type I error from multiple comparisons, the alpha level was adjusted using the Bonferroni correction, due to multiple correlations, i.e. alpha level = 0.05/21 = 0.00238 (21 is the number of correlations, one for each receptor; 5-HT 3 and D 4 were excluded due to lack of data) [23] . For significant correlations, the relationship between the risk for reporting diabetes and occupancy on receptors was further investigated with univariate linear regression. The dependent variable was the aROR for diabetes and the exploratory variable was receptor occupancy. All analyses were conducted in R version 3.3.2 [24] .
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www. guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY [19] , and follow The Concise Guide to PHARMACOLOGY 2017/18 [25] [26] [27] .
Results

Study population and receptor occupancy
Of the total of 4 704 663 reports submitted in FAERS between 2004 and 2017Q2, the final sample consisted of 136 028 reports concerning the 22 antidepressants after the aforementioned data cleaning and exclusions (Figure 1 ). Diabetes was identified in 1610 reports, which is 1.18% of the final sample. The demographics and medical characteristics are displayed in Table 1 . The age of cases was greater than non-cases (P < 0.001), whereas no difference in gender was observed and the female-to-male ratio was about 2.26. Use of hyperglycaemic drugs was associated with cases (P < 0.001). Difference in reporting year was observed (P < 0.001), and reports regarding cases were submitted in earlier years. The pharmacodynamic profile of the antidepressants is presented in Figure 2 and Table S2 .
Disproportionality analysis
The number of cases and the aROR for diabetes for antidepressants are presented in Figure 3 and Occupancy of antidepressants on human transporters and receptors. The occupancy was calculated using the pharmacological receptor theory, i.e. occupancy = 100 * [Cr]/([Cr] + Ki). The inhibitory constant (Ki) was extracted from PDSP and IUPHAR databases and the unbound concentration (Cr) was calculated using the unbound fraction and the maximum therapeutic reference range, except for nefazodone. Colour key displays the degrees of occupancy (%) Figure 3 Disproportionality analysis in FAERS for the association between diabetes and individual antidepressants. The differential risk for reporting diabetes of individual antidepressants in comparison to the other antidepressants was quantified as adjusted reporting odds ratio (aROR). The ROR was adjusted to age, gender, reporting year, and use of hyperglycaemic drugs in multivariate logistic regression. Trimipramine, maprotiline, desipramine had less than three reports, so they are not presented 
Discussion
This study investigated the risk for diabetes of individual antidepressants and its relationship with their pharmacodynamic profile using a combined pharmacovigilancepharmacodynamic approach. The risk for reporting diabetes was estimated with disproportionality analysis of the FAERS database. Individual antidepressants seem to carry differential risk for diabetes. Most of the tricyclic antidepressants, i.e. imipramine, amitriptyline, nortriptyline and doxepin, as well as sertraline and mirtazapine, were associated with diabetes in comparison to the other antidepressants. The risk for diabetes seems to correlate with the pharmacodynamic profile of antidepressants. Higher degrees of occupancy on H 1 and muscarinic receptors, except for M 2 , seem to be related with higher risk for diabetes. However, these receptor mechanisms could not explain the disproportionate signal for sertraline.
The better-studied antipsychotics can provide insights on receptor mechanisms of glucose intolerance. Antipsychotics seem to interfere with central and peripheral metabolic regulation and they could promote obesity, insulin resistance and beta cell dysfunction. Central energy balance centres express 5-HT 2C and H 1 receptors, and their antagonism could induce weight gain as well as disturbances in peripheral flow of autonomic nervous system and glucose intolerance. Pancreatic islets seem to express muscarinic, serotonergic receptors and serotonin transporter, and their inhibition could disrupt insulin secretion and glucose handling. Adrenergic and dopaminergic signalling may also play important roles in metabolic side effects. Τhe net result is a complex interplay between central and peripheral mechanisms [3, 28] . In accordance with Figure 4 Pearson's correlation coefficients (r) and their P-values of the relationship between aROR for diabetes and the occupancy on each receptor/transporter. The receptors 5-HT 3 and D 4 were not analysed due to lack of pharmacodynamic data. P-values were adjusted to Bonferroni correction due to multiple correlations (21) to 0.00238. Significant correlations were observed for occupancies on the muscarinic receptors, except for M 2 , and the histamine H 1 receptor. Degrees of occupancy less than 0.1% were excluded, as well as antidepressants with less than three reports with diabetes the above mechanisms, a positive correlation between the risk for diabetes of antidepressants and degrees of occupancy on H 1 and muscarinic receptors were observed in FAERS. Additionally, non-significant moderate to strong correlations were also identified for NET, 5-HT 2C and D 3 .
Our results are in agreement with previous studies, which associate the risk for diabetes with the pharmacodynamic profile of antidepressants. A cross-sectional study of patients with bipolar disorders suggested that antidepressants with strong H 1 antagonistic properties, but not in general antidepressants, are associated with metabolic syndrome. An inverse association between the inhibitory constant (Ki) for H 1 and prevalence of metabolic syndrome was also observed [6] . In addition, a case-control study suggested that antidepressants with antagonistic properties on M 3 are associated with incident type 2 diabetes [7] . A disproportionality analysis in the pharmacovigilance database of the WHO has also suggested that antidepressants might associate with diabetes, with a more pronounced risk for antidepressants with affinities to H 1 , 5-HT 2C and NET [5] . These studies used pharmacodynamic classifications of antidepressants to investigate receptor mechanisms, rather than assessing directly the role of the pharmacodynamic profile. The direct combination of pharmacovigilance with pharmacodynamic data has been proposed to study receptor mechanisms of adverse events in safety reports databases. This approach has been applied in VigiBase to study drug-induced arrhythmias [29] , antipsychotic-induced diabetes [4] , antipsychotic-induced movement disorders [8] and cardiac failure induced by protein kinase inhibitors [9] . Herein, we used a similar approach Figure 5 Univariate linear regression models of the relationship between the adjusted reporting odds ratio (aROR) for diabetes and the occupancy on (A) M 1 , (B) M 3 , (C) M 4 , (D) M 5 and (E) H 1 of individual antidepressants. The line demonstrates the linear regression model and the grey area demonstrates the 95% CI of the linear regression model. Degrees of occupancy less than 0.1% were excluded, as well as antidepressants with less than three reports with diabetes Safety signal of antidepressants and type 2 diabetes in FAERS, which can also be used to study receptor mechanisms of adverse events [30] .
Antagonism of H 1 seems to explain the association between imipramine, amitriptyline, nortriptyline, doxepin and mirtazapine with diabetes, as these antidepressants have the highest degrees of occupancy on H 1 . Except for mirtazapine, these antidepressants also have high degrees of occupancy on muscarinic receptors, but without displaying marked selectivity among M 1 to M 5 receptors. Due to the small number of antidepressants, multivariable analysis could not be utilized to assess the effect of both receptor systems. Other antidepressants with high occupancies on H 1 , such as trimipramine, maprotiline and desipramine, had small and potentially insufficient numbers of reports in order to raise disproportionality signals. The role of 5-HT 2A/C antagonism has also been suggested in psychotropic-induced diabetes, especially in antipsychotics [3, 4] . However, a significant correlation was not observed, which is also supported by the fact that nefazodone and trazodone were not associated with diabetes. Nefazodone and trazodone have relatively high degrees of occupancy on 5-HT 2A/C , but they lack high degrees of occupancy on H 1 and muscarinic receptors. Despite the proposed role of NET inhibition [5] , milnacipran and duloxetine were also not associated with diabetes. These drugs have relatively high degrees of occupancy on NET but they also lack occupancy on H 1 or muscarinic receptors.
On the other hand, the SSRI sertraline was associated with diabetes, despite its low degrees of occupancy on H 1 , muscarinic or even 5-HT 2C and NET. As a result, other mechanisms cannot be excluded. The role of SERT inhibition seems to be complex. Short-term treatment with SERT inhibitors may be linked to weight loss [31] , probably due to increased extracellular serotonin and indirect stimulation of 5-HT 1B and 5-HT 2C in energy balance centres, which promote satiety states [32] . However, long-term treatment may be linked to weight gain and glucose intolerance [31] , probably due to compensatory mechanisms and/or pancreatic SERT inhibition. At least some antidepressants, i.e. fluoxetine, paroxetine and clomipramine, may also have direct oxidative and cytotoxic effects on pancreatic beta cells, independent of SERT inhibition [33] . Furthermore, a placebo-controlled randomized trial in depressed non-human primates suggested that chronic administration of sertraline decreases adiponectin, independently of effects on adiposity. Decreased levels of adiponectin could promote insulin resistance and atherosclerosis [32] .
The present study has certain limitations. Disproportionality analysis is a statistical method used to identify potential significant drug-event combinations, highlighting combinations which need further clinical validation [10, 13] . It cannot remove the absolutely necessary step of a careful clinical causality assessment, thus, association found is not causation. There might be other reasons leading to an association and thus confounding the results: confounding by indication, by underlying diseases and by concomitant drugs. Regarding a possible indication bias, tricyclic antidepressants are considered for second-line treatment in depression [34] , while metabolic dysregulation has been associated with chronicity of illness and poor response to antidepressants [35] . However, there is evidence of the biological plausibility of tricyclic antidepressant-induced glucose dysregulation; a randomized double-blind study suggested that nortriptyline had direct hyperglycaemic effects in comparison to placebo in diabetic patients with active major depression [36] . A further limitation of our study was that pharmacovigilance databases, like FAERS, are mostly based on spontaneous reports and the quality of information may be suboptimal leading to case misclassification bias, while underreporting still remains a major concern of spontaneous adverse drug reactions reporting systems [37, 38] . Nevertheless, reporting rates are suggested to be similar in drugs of the same therapeutic class [39] , such as antidepressants. The estimation of occupancy on receptors also has inherent limitations. Since concentrations of drugs in the cerebrospinal fluid are scarcely available, total blood concentrations were used to estimate occupancy on receptors, such as those presented in therapeutic reference ranges of recommended doses of antidepressants [4] . In addition, the occupancy on receptors based on the pharmacological receptor theory is not directly associated with the degree of pharmacological activity [8, 17] . However, in clinical setting, the action of the selected antidepressants is explained mostly by antagonistic properties on receptors and transporters. Finally, regarding the linear regression analysis, the moderate number of drugs prohibit multivariate analysis and could limit the statistical power [40] . Despite these limitations, the major strength of this study is the large number of reports exposed to antidepressants (136 028) and the attempts to minimize confounding and bias on the available data.
In conclusion, our results suggest a disproportionality signal of antidepressant-induced diabetes with plausible pharmacological mechanism being the antagonism on muscarinic and H 1 receptors, but other mechanisms should also be expected. Taking into account the clinical and pharmacological aspects of this association, an appropriate causality assessment is needed to validate it and to proceed to further investigation through post-marketing long-term safety studies as appropriate.
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http://onlinelibrary.wiley.com/doi/10.1111/bcp.13699/suppinfo Table S1 Concomitant drugs. Reports with concomitant antipsychotics (first or second generation) or combination of antidepressant drugs were excluded from further analysis, due to targeting the same receptors as well as for the notoriety bias of some antipsychotics in FAERS. Reports with concomitant antidiabetic medication were excluded, since they indicate pre-existing diabetes, rather than incident diabetes. Use of hyperglycaemic was included as covariates in logistic regression to adjust the reporting odds ratio for diabetes. 
